# Anju Mathew

> Anju Mathew is the Atlanta-based co-founder and CEO of OncoLens, an oncology-focused health-technology company that organizes multidisciplinary collaboration, patient data and clinical workflows in one platform. An industrial engineer by training and a Kellogg MBA, she moved through software engineering, consulting, corporate strategy and healthcare innovation before founding two companies in cancer technology. Her career is a study in turning coordination problems into usable systems.

- **Role:** CEO and Co-Founder at OncoLens
- **Organizations:** OncoLens, McKesson, LumaMed, Thomson Reuters, Kearney, IBM, i2 Technologies, Atlanta Technology Angels, illuma Care Connections
- **Education:** Bachelor of Engineering in Industrial Engineering, Indian Institute of Technology Roorkee, MBA in Strategy and Marketing, Northwestern University - Kellogg School of Management
- **Known for:** Co-founded two cancer-technology companies: LumaMed and OncoLens., Led OncoLens through a $7.25 million Series A in 2021 and a $16 million Series B in 2024., Named a Georgia Titan 100 honoree in 2023, 2024 and 2025.

## Career timeline

- **1999-2000** — Worked as a software engineer at IBM.
- **2000-2002** — Worked as an associate consultant at i2 Technologies.
- **2004-2007** — Worked as a management consultant at Kearney.
- **2007-2008** — Worked in strategic consulting at Thomson Reuters.
- **2008-2012** — Co-founded LumaMed, a medical-device company focused on cancer imaging.
- **2012-2014** — Worked in corporate strategy and business development at McKesson.
- **2014-2017** — Led technology innovation roles at McKesson Medical-Surgical, ultimately serving as head of technology and innovation.
- **2015-2018** — Participated as an angel investor with Atlanta Technology Angels.
- **2016-2018** — Served on the board of illuma Care Connections.
- **2017-present** — Co-founded and leads OncoLens as CEO.
- **2021** — OncoLens announced a $7.25 million Series A.
- **2024** — OncoLens raised a $16 million Series B and ranked No. 1296 on the Inc. 5000.

## Achievements

- Co-founded two cancer-technology companies: LumaMed and OncoLens.
- Led OncoLens through a $7.25 million Series A in 2021 and a $16 million Series B in 2024.
- Named a Georgia Titan 100 honoree in 2023, 2024 and 2025.
- Selected as a Women in Technology Woman in Science finalist in 2021 and 2023.
- Recognized among the Top 100 Northwestern Alumni in Technology in 2021.
- Associated with Technology Association of Georgia honors for impact and innovation in 2020.
- Co-authored oncology research presented through ASCO and other professional venues.

## Latest updates

- **2026-04** — OncoLens announced that research co-authored by Mathew on cost and accuracy in large-scale biomarker extraction using large language models was selected for presentation at EURAICA 2026.
- **2026-02** — Mathew highlighted OncoLens’ nationwide collaboration with The Jackson Laboratory to extend expert-led genomic tumor boards to community cancer centers.
- **2025-05** — Recognized among the 2025 Georgia Titan 100 honorees.
- **2024-10** — OncoLens closed a $16 million Series B co-led by BIP Capital and Cross Border Impact Ventures.
- **2024-08** — OncoLens ranked No. 1296 on the 2024 Inc. 5000.

## Links

- Website: https://oncolens.com
- LinkedIn: https://www.linkedin.com/in/anju-mathew-045267
- Twitter/X: https://twitter.com/oncolens/
- Facebook: https://www.facebook.com/OncoLens/

---

Profile page: https://yespress.io/anju-mathew
Published by YesPress — https://yespress.io
Last updated: 2026-08-28